ホーム 計算ツール
代理店ログイン

Venetoclax

カタログ番号 T2119   CAS 1257044-40-8
別名: GDC-0199, ABT 199, ABT-199, ABT199

Venetoclax (ABT-199) is a Bcl-2 inhibitor (Ki<0.01 nM) with potent, selective, and orally active properties. Venetoclax has a 3-order-of-magnitude lower affinity for Bcl-xL and Bcl-W (Kis=48/245 nM). Venetoclax induces autophagy and apoptosis.

TargetMolの製品は全て研究用試薬です。人体にはご使用できません。 また、個人の方への販売は行っておりません。
Venetoclax Chemical Structure
Venetoclax, CAS 1257044-40-8
パッケージサイズ 在庫状況 単価(税別)
サンプルについてお問い合わせ
5 mg 在庫あり ¥ 11,000
10 mg 在庫あり ¥ 16,000
50 mg 在庫あり ¥ 20,500
100 mg 在庫あり ¥ 27,000
500 mg 在庫あり ¥ 88,000
1 g 在庫あり ¥ 137,000
1 mL * 10 mM (in DMSO) 在庫あり ¥ 15,500
ご確認事項

1. 1研究室・グループあたり最大5製品までお申し込みいただけます。 同一製品は1回のみとなります。

2. 1回につき最大2製品までのお申し込みが可能です。

3. 2回目以降をご希望の際は、前回ご提供のサンプルの実験結果をオンラインでご提供いただく必要がございます。

4. 2023 年 1 月 20 日より前にサンプルをお申し込みいただいたお客様は、2023 年の無料申請枠にはカウントされませんが、以前の実験結果をご提供いただく必要があります。

Get quote
バッチを選択  
バッチの詳細情報はお問い合わせください
生物学的特性に関する説明
化学的特性
保存条件 & 溶解度情報
説明 Venetoclax (ABT-199) is a Bcl-2 inhibitor (Ki<0.01 nM) with potent, selective, and orally active properties. Venetoclax has a 3-order-of-magnitude lower affinity for Bcl-xL and Bcl-W (Kis=48/245 nM). Venetoclax induces autophagy and apoptosis.
ターゲット&IC50 BCL-XL:48 nM (Ki, cell free), BCL2:<0.01 nM (Ki, cell free)
In vitro METHODS: Eleven human T-cell acute lymphoblastic leukemia cells T-ALL were treated with Venetoclax (0-12 μM) for 48 h. Cell viability was measured by Celltiter-Glo Luminescent Cell Viability Assay.
RESULTS: The IC50 values of Venetoclax against 11 T-ALL species ranged from 0.2-10 μM. [1]
METHODS: Human acute lymphoid leukemia cells RS4;11 were incubated with Venetoclax (0.01-5 μM) for 3.5 h. Caspase-3/7 activity was assessed using the Caspase-GLO kit.
RESULTS: Venetoclax induced the activation of caspases, which is one of the characteristics of apoptosis. [2]
METHODS: Human primary HCL leukemia cells were treated with Venetoclax (0.1-1 μM) for 24 h. Cell death was detected using Flow Cytometry method.
RESULTS: Venetoclax significantly increased cell death in HCL cells in a dose-dependent manner. [3]
In vivo METHODS: To test the antitumor activity in vivo, Venetoclax (100 mg/kg in 60% PG+30% PEG 400+10% ethanol) was orally administered once daily for twenty-one days to C.B-17 SCID-beige mice bearing human diffuse large B-cell lymphoma Toledo.
RESULTS: Venetoclax significantly inhibited the growth of Toledo tumor (TGImax=93%, TGD=220%). [2]
METHODS: To assay anti-tumor activity in vivo, Venetoclax (50 mg/kg in 10% ethanol+30% PEG 400+60% Phosal 50PG, administered orally once daily) and anti-PD-1 (10 mg/kg in PBS, administered intraperitoneally three times every four days) were administered to C57BL/6 mice harboring mouse colorectal carcinoma tumor MC38 for fourteen days.
RESULTS: Venetoclax enhances the antitumor efficacy of immune checkpoint inhibitors (ICIs) and increases PD-1+ T effector memory cells. Venetoclax does not impair human T-cell function in response to antigenic stimulation in vitro, nor does it antagonize anti-PD-1-induced T-cell activation. [4]
キナーゼ試験 The equilibrium binding experiments of fluorescent peptides to Bcl-xL protein were performed in an Analyst 96-well plate reader under the following conditions: each individual well in a 96-well assay plate contained 5 μl DMSO, 15 nM fluorescent peptide, and increasing concentrations (from 0 to 2.24 μM) of Bcl-xL protein in assay buffer in a final volume of 125 μl. The plate was mixed on a shaker for 1 min and incubated at room temperature for an additional 15 min. The polarization in millipolarization units (mP) was measured at room temperature with an excitation wavelength at 485 nm and an emission wavelength at 530 nm. For assay stability testing, a plate containing a binding experiment was measured at different times over a 24-h period. Between each reading, the plate was covered with parafilm to prevent any solution evaporation. To determine the effect of DMSO on the assay, binding experiments were performed under conditions similar to those described above except that the amount of DMSO was varied from 0 to 4 to 8%. All experimental data were analyzed using Prism 3.0 software and Kd values were generated by fitting the experimental data using a sigmoidal dose-response nonlinear regression model [1].
細胞研究 RS4;11 cells were seeded at 50,000 per well in 96-well plates and treated with compounds diluted in half-log steps starting at 1 μM and ending at 0.00005 μM. All other leukemia and lymphoma cell lines were seeded at 15,000–20,000 cells per well in the appropriate medium and incubated with ABT-199 or navitoclax for 48 h. Effects on proliferation were determined using Cell TiterGlo reagent. EC50 values were determined by nonlinear regression analysis of the concentration-response data. Mouse FL5.12–BCL-2 and FL5.12–BCL-XL cells were propagated and assessed as described previously. Bak?/? Bax?/? double knockout mouse embryonic fibroblasts were seeded into 96-well microtiter plates at 5,000 cells per well in DMEM supplemented with 10% FBS. ABT-199 in the same culture medium was added in half-log dilutions starting at 5 μM. The cells were then incubated at 37 °C (5% CO2) for 48 h, and the effects on proliferation were determined using Cell TiterGlo reagent according to the manufacturer's instructions [1].
動物実験 Female C.B-17 SCID mice (DoHH2 and Granta-519 xenografts) and female C.B-17 SCID-beige mice (RS4;11 and Toledo xenografts) were inoculated with 1 × 10^6 (DoHH2) or 5 × 10^6 (Granta-519, Toledo and RS4;11) cells subcutaneously in the right flank. The inoculation volume (0.2 ml) comprised a 50:50 mixture of cells in growth media and Matrigel. Electronic calipers were used to measure the length and width of each tumor 2–3 times per week. Tumor volume was estimated by applying the following equation: volume = length × width2/2. When tumors reached approximately 220 mm3, mice were size matched (day 0) into treatment and control groups. All xenograft trials were conducted using ten mice per group, and all mice were ear tagged and monitored individually throughout the studies. ABT-199 was formulated for oral dosing in 60% phosal 50 propylene glycol (PG), 30% polyethylene glycol (PEG) 400 and 10% ethanol, and bendamustine and rituximab were formulated in accordance with the manufacturer's instructions. ABT-199 was delivered approximately 2 h before bendamustine or bendamustine plus rituximab. TGImax was calculated as the greatest treatment response using the following equation: TGImax = (1 ? mean tumor volume of the treated group/mean tumor volume of the vehicle control group) × 100. The TGD (%) was determined as the percentage increase of the median time period for the treatment group to reach an arbitrary tumor volume of 1,000 mm3 relative to the vehicle control group. A complete tumor regression response was the portion of the population with tumors ≤25 mm3 for at least three consecutive measurements [1].
別名 GDC-0199, ABT 199, ABT-199, ABT199
分子量 868.44
分子式 C45H50ClN7O7S
CAS No. 1257044-40-8

保存条件

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度情報

H2O: < 1 mg/mL (insoluble or slightly soluble)

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

DMSO: 100 mg/mL (115.15 mM)

参考文献

1. Peirs S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014 Dec 11;124(25):3738-47. 2. Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. 3. Vereertbrugghen A, et al. In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia. Front Oncol. 2021 Jul 26;11:598319. 4. Kohlhapp FJ, et al. Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade. Cancer Discov. 2021 Jan;11(1):68-79. 5. Capoci I R G, Faria D R, Sakita K M, et al. Repurposing approach identifies new treatment options for invasive fungal disease[J]. Bioorganic chemistry. 2019 Mar;84:87-97.

引用文献

1. Lima K, Pereira-Martins D A, de Miranda L B L, et al.The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy.Blood cancer journal.2022, 12(11): 1-11. 2. Pan G, Zhong M, Yao J, et al.Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.Journal of Cancer Research and Clinical Oncology.2022: 1-17. 3. Gao P, Zhang W, Fang X, et al.Simultaneous quantification of venetoclax and voriconazole in human plasma by UHPLC-MS/MS and its application in acute myeloid leukemia patients.Journal of Pharmaceutical and Biomedical Analysis.2023: 115279. 4. Li Z, Pan G, Zhong M, et al.High-Throughput Drug Screen for Potential Combinations With Venetoclax Guides the Treatment of Transformed Follicular Lymphoma.International Journal of Toxicology.2023: 10915818231178693. 5. e Silva, Catarina Sofia Mateus Reis, et al. Embelin potentiates venetoclax-induced apoptosis in acute myeloid leukemia cells. Toxicology in Vitro. (2021): 105207. 6. Takei H, Coelho‐Silva J L, Leal C T, et al. Suppression of multiple anti‐apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. Cancer Science. 2022, 113(2): 597. 7. Suarez M, Blyth G T, Mina A A, et al. Inhibitory effects of Tomivosertib in acute myeloid leukemia. Oncotarget. 2021, 12(10): 955. 8. Tang J, Yao C, Liu Y, et al. Arsenic trioxide induces expression of BCL-2 expression via NF-κB and p38 MAPK signaling pathways in BEAS-2B cells during apoptosis. Ecotoxicology and Environmental Safety. 2021, 222: 112531. 9. Tan M, Ren F, Yang X. Anti-HBV therapeutic potential of small molecule 3, 5, 6, 7, 3′, 4′-Hexamethoxyflavone in vitro and in vivo. Virology. 2021 10. Lee J B, Khan D H, Hurren R, et al. Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production. Blood. 2021 Jul 22;138(3):234-245. doi: 10.1182/blood.2020009081.
隠し

関連化合物ライブラリー

この製品は下記化合物ライブラリに含まれています:
Anti-Cancer Approved Drug Library Anti-Cancer Drug Library Inhibitor Library Drug Repurposing Compound Library Highly Selective Inhibitor Library Anti-Cancer Active Compound Library EMA Approved Drug Library Anti-Cancer Clinical Compound Library Covalent Inhibitor Library Pediatric Drug Library

関連製品

同一標的の関連化合物
BI-3812 (R)-(-)-Gossypol acetic acid Coronarin D Mcl1-IN-9 Myricanone 3',6-Disinapoylsucrose Kurarinone Sabutoclax

投与量変換

You can also refer to dose conversion for different animals. 詳細

In vivo投与量計算 (透明溶液)

ステップ1: 以下の情報を入力してください
投与量
mg/kg
動物の平均体重
g
動物あたりの投与量
ul
動物数
溶媒の組成を入力してください
% DMSO
%
% Tween 80
% ddH2O
計算する リセット

計算器

モル濃度計算機
希釈計算機
再構成計算
分子量計算機
=
X
X

モル度計算機では以下の計算が可能です

  • 既知の体積と濃度の溶液を調製するために必要な化合物の質量
  • 質量が既知の化合物を目的の濃度まで溶解させるのに必要な溶液の量
  • 特定の体積の中に既知の質量の化合物を入れて得られる溶液の濃度
参考例

モル濃度計算機を使用したモル濃度計算の例
化合物の分子量が197.13g/molである場合、10mlの水に10mMのストック溶液を作るのに必要な化合物の質量はどれくらいですか?
[分子量(MW)]の欄に[197.13]と入力してください
[濃度]ボックスに10と入力し、正しい単位(millimolar)を選択します
[容量]ボックスに10と入力し、正しい単位(milliliter)を選択します
計算を押します
答えの19.713mgが質量欄に表示されます

X
=
X

溶液を作るのに必要な希釈率の計算

溶液の調製に必要な希釈率の算出
希釈計算機は、既知の濃度の原液をどのように希釈するかを計算することができる便利なツールです。V1を計算するためにC1、C2&V2を入力します。

参考例

Tocrisの希釈計算器を用いた希釈計算の一例
50μMの溶液を20ml作るためには、10mMの原液を何ml必要ですか?
C1V1=C2V2という式を用いて、C1=10mM、C2=50μM、V2=20ml、V1を未知数とします。
濃度(開始)ボックスに10を入力し正しい単位(millimolar)を選択してください
濃度(終了)ボックスに50を入力し正しい単位(millimolar)を選択してください
体積(終了)ボックスに20を入力し正しい単位(millimolar)を選択してください
計算を押します
100 microliter (0.1 ml) という答えが体積(開始)ボックスに表示されます。

=
/

バイアルを再構成するのに必要な溶媒の量を計算する.

再構成計算機を使えば、バイアルを再構成するための試薬の量をすぐに計算することができます.
試薬の質量と目標濃度を入力するだけで計算します。

g/mol

化合物の化学式を入力して、そのモル質量や元素組成を計算します

Tヒント:化学式は大文字と小文字を区別します。: C10H16N2O2 c10h16n2o2

化合物のモル質量(分子量)を計算する手順:
化学物質のモル質量を計算するには、その化学式を入力し、「計算」をクリックしてください。.
分子質量、分子量、モル質量、モル重量の定義:
分子質量(分子量)とは、物質の1分子の質量であり、統一された原子質量単位(u)で表されます。(1uは炭素12の1原子の質量の1/12に等しい)
モル質量(molar weight)とは、ある物質の1モルの質量のことで、単位はg/molです。

bottom

技術サポート

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.

Keywords

Venetoclax 1257044-40-8 Apoptosis Autophagy BCL bioavailable GDC0199 GDC-0199 orally inhibit Inhibitor Bcl-2 Family GDC 0199 ABT 199 ABT-199 ABT199 inhibitor